The health sector posted modest gains on Tuesday, with a handful of drug developers such as Eli Lilly, Biogen and Merck outperforming the broader index.
Hims and Hers Health inked a deal to acquire European health platform Zava. Hims stock fell.
Roche said a drug combination, Tecentriq combined with lurbinectedin, shows survival benefits for patients with extensive-stage small-cell lung cancer. The Swiss pharmaceutical company said that late-stage trials showed the combination led to a 46% reduction in the risk of the disease progressing or death, and 27% reduction in the risk of death. Roche shares fell in the European session.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
06-03-25 1726ET
